Alecinix 150mg (Alectinib)

Alecinix 150mg (Alectinib) is a medication used for the treatment for non-small cell lung cancer. It works by blocking Anaplastic lymphoma kinase. It is sold under the brand name Alecensa.

Alectinib was approved for the treatment of ALK fusion-gene postive in japan in july 2014 for the treatment of  recurrent, unresectable or advance non-small cell lung cancer and it was approved by FDA in  2015.

Alecinix 150mg (Alectinib): Mechanism of Action

Alectinib is an oral medication classified as a tyrosine kinase inhibitor. It works by selectively targeting and blocking specific abnormal proteins, including anaplastic lymphoma kinase (ALK), which drives the growth of cancer cells. By inhibiting ALK, Alectinib hinders the proliferation and survival of cancerous cells.

Alecinix 150mg (Alectinib): Side Effects

Alectinib may cause some side effects, which vary from patient to patient. Common side effects may include but are not limited to nausea, fatigue, diarrhea, constipation, muscle pain, and changes in appetite. It is important to consult with a healthcare professional for personalized guidance and management of side effects.

Alecinix 150mg (Alectinib): Package insert

For comprehensive details on Alectinib’s administration, dosing, precautions, contraindications, and potential drug interactions, please refer to the official package insert provided by the manufacturer or consult your healthcare professional.

You also can check briganix 180 mg which is also used to treat non-small cell lung cancer.

Alecinix 150mg (Alectinib): Life Expectancy and Success Rate

Alectinib is an effective medicine that are being used since 2014 to treat anaplastic lymphoma kinase positive non-small cell lung cancer. Alectinib may increase the life expectency of patietn 34.8 month compared to Crizotinib which may increase 10.9 month.